miscsubjectsAI governance
Evidence review

Tesamorelin for Sciatica: Evidence on Repair Layers vs Symptom Suppression

bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `tesamorelin-sciatica`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/tesamorelin-sciatica

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-sciatica/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tesamorelin-sciatica/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tesamorelin-sciatica/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tesamorelin-sciatica/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down if you have Sciatica

  1. Sciatica is nerve pain along the sciatic nerve — often from disc herniation or stenosis compressing a root.
  2. The nerve is signaling damage/compression; suppressing pain does not uncompress the nerve.

Why Tesamorelin might help you

  1. You have Sciatica — breakdown is outpacing repair.
  2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.
  3. This article centers Tesamorelin; see other sections for bpc-157, tb-500, ara-290 — different layers, same condition.

Why BPC-157 might help you

  1. You have Sciatica — breakdown is outpacing repair.
  2. What keeps failing: Poor blood supply at injury, weak collagen organization, slow tissue turnover.
  3. What BPC-157 is studied to do: Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.
  4. Therefore for you: If that layer is part of your problem, BPC-157 is discussed because it targets repair (structure / tissue) — not because it masks pain.

Why TB-500 might help you

  1. You have Sciatica — breakdown is outpacing repair.
  2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
  3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
  4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

Why ARA-290 might help you

  1. You have Sciatica — breakdown is outpacing repair.
  2. What keeps failing: Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.
  3. What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.
  4. Therefore for you: If that layer is part of your problem, ARA-290 is discussed because it targets repair (nerve / innervation) — not because it masks pain.

How these fit together

Each compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.

  • Tesamorelin → GH axis / visceral fat
  • BPC-157 → structure / tissue
  • TB-500 → inflammation clearance / repair-cell migration
  • ARA-290 → nerve / innervation

Primary focus of this slug: Tesamorelin. Others are in scope because the same condition breaks down on multiple layers.

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 4
  • Claims tagged human evidence: 2
  • Claims tagged preclinical (animal/lab): 2
  • Claims tagged anecdotal: 0
  • Reddit posts catalogued: 0
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 4

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.42 / 1.00 — low–moderate — mostly preclinical

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Tesamorelin for Peripheral Nerve Injury (source s1)

Phase 2 trial recruiting for tesamorelin in peripheral nerve injury recovery.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury (source s2)

Rat study on BPC-157 improving transected sciatic nerve healing and function.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

ARA 290 for treatment of small fiber neuropathy in sarcoidosis (source s3)

Human trial showing ARA-290 benefits in small fiber neuropathy symptoms.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Thymosin β4 Promotes the Recovery of Peripheral Neuropathy (source s4)

Animal study on thymosin beta-4 improving sciatic nerve parameters in neuropathy model.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

Peptide components (collapsible embeds)

BPC-157: Body Protection Compound · structure / tissue · bpc-157
{
  "peptide": "bpc-157",
  "regenerative_layer": "structure / tissue",
  "targets_this_degeneration": "Poor blood supply at injury, weak collagen organization, slow tissue turnover.",
  "proposed_regeneration": "Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.",
  "evidence_in_ledger": {
    "human_claims": 26,
    "preclinical_claims": 4,
    "anecdote_claims": 113,
    "studies_catalogued": 35
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/bpc-157"
}

BPC-157 is a 15-amino-acid peptide first isolated from human gastric juice. It is one of the most-studied and least-approved compounds in the recovery world: more than a hundred animal papers describe it healing tendon, gut, muscle, nerve, and bone, roughly three small human reports exist, and in July 2026 an FDA advis…

Full bpc-157 article →
TB-500 (Thymosin Beta-4) · inflammation clearance / repair-cell migration · tb-500
{
  "peptide": "tb-500",
  "regenerative_layer": "inflammation clearance / repair-cell migration",
  "targets_this_degeneration": "Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.",
  "proposed_regeneration": "Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.",
  "evidence_in_ledger": {
    "human_claims": 4,
    "preclinical_claims": 3,
    "anecdote_claims": 1,
    "studies_catalogued": 15
  },
  "confidence_0_to_1": 0.87,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/tb-500"
}

TB-500 is sold as a healing peptide, and the first thing to understand is that "TB-500" and the peptide in the actual research trials are usually not the same molecule. The trials used full-length thymosin beta-4 (Tβ4), a 43-amino-acid protein the body makes in nearly every tissue. Most vials sold as "TB-500" contain a…

Full tb-500 article →
ARA-290 (Cibinetide) · nerve / innervation · ara-290
{
  "peptide": "ara-290",
  "regenerative_layer": "nerve / innervation",
  "targets_this_degeneration": "Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.",
  "proposed_regeneration": "Studied for nerve repair and small-fiber regeneration in neuropathy models.",
  "evidence_in_ledger": {
    "human_claims": 3,
    "preclinical_claims": 3,
    "anecdote_claims": 1,
    "studies_catalogued": 9
  },
  "confidence_0_to_1": 0.72,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/ara-290"
}

ARA-290, also called cibinetide, is an 11-amino-acid peptide cut from a single face of the erythropoietin molecule. It keeps EPO's tissue-repair signal and throws away EPO's blood-building one — and that split is the entire point of the drug. It is the rarest and, in one specific way, the best-evidenced compound in a d…

Full ara-290 article →

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Explore this article's relationships

Sciatica · condition map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
Evidence · 4 sources · swipe →chain ea941231b21b · verify chain · provenance
Evidence ledger 4 · tier-ranked · API
human
One ongoing phase 2 trial tests tesamorelin for peripheral nerve injury recovery.
sources: s1
preclinical
Rat studies show BPC-157 improved axonal regeneration and functional recovery after sciatic nerve transection.
sources: s2
humanlow confidence
ARA-290 improved neuropathic symptoms and corneal nerve fiber density in human small fiber neuropathy trials.
sources: s3
preclinicallow confidence
TB-500 improved sciatic nerve function in diabetic neuropathy animal models.
sources: s4
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-29 23:14
Tesamorelin for Sciatica: Evidence on Repair Layers vs Symptom Suppression · 4 claims · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: Tesamorelin for Sciatica
Slug: tesamorelin-sciatica
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"multi_stack","condition":"Sciatica","condition_key":"sciatica","primary_peptide":"tesamorelin","peptides_in_scope":[{"id":"tesamorelin","name":"Tesamorelin"},{"id":"bpc-157","name":"BPC-157"},{"id":"tb-500","name":"TB-500"},{"id":"ara-290","name":"ARA-290"}],"drugs_in_scope":[],"weigh
it output
{
  "slug": "tesamorelin-sciatica",
  "title": "Tesamorelin for Sciatica: Evidence on Repair Layers vs Symptom Suppression",
  "body": "## What's breaking down if you have Sciatica\n\nSciatica involves nerve pain along the sciatic nerve, often from disc herniation or spinal stenosis compressing a nerve root. The nerve signals damage or compression. Suppressing pain signals does not address the compression or the underlying tissue breakdown. Repair pathways must outpace ongoing degeneration for symptoms to resolve long-term. Mechanical factors like excess visceral fat can add compressive load on the lumbar spine.\n\n## Why Tesamorelin might help you\n\n1. You have Sciatica — breakdown is outpacing repair.\n2. Therefore for you: If visceral fat or growth hormone axis issues contribute to mechanical load or poor tissue turnover, Tesamorelin is discussed because it targets the GH axis and visceral fat reduction — not because it masks pain.\n3. This article centers Tesamorelin; see other sections for BPC-157, TB-500, ARA-290 — different layers, same condition.\n\n## Why BPC-157 might help you\n\n1. You have Sciatica — breakdown is outpacing repair.\n2. What keeps failing: Poor blood supply at injury sites, weak collagen organization, slow tissue turnover.\n3. What BPC-157 is studied to do: Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue
eb894d9f8ccc70f5
Machine verification: /api/articles/tesamorelin-sciatica/contributions
Ask this article · 6 suggested prompts

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "One ongoing phase 2 trial tests tesamorelin for peripheral nerve injury recovery."?
ask tesamorelin-sciatica claim c1 · paste includes §SELF
What does the ledger say about this (preclinical tier): "Rat studies show BPC-157 improved axonal regeneration and functional recovery after sciatic nerve transection."?
ask tesamorelin-sciatica claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "ARA-290 improved neuropathic symptoms and corneal nerve fiber density in human small fiber neuropathy trials."?
ask tesamorelin-sciatica claim c3 · paste includes §SELF
What does the ledger say about this (preclinical tier): "TB-500 improved sciatic nerve function in diabetic neuropathy animal models."?
ask tesamorelin-sciatica claim c4 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about Tesamorelin for Sciatica: Evidence on Repair Layers vs Symptom Suppression — and what would you need me to tell you first?
ask tesamorelin-sciatica condition gaps · paste includes §SELF
What good and bad outcomes are documented for Tesamorelin for Sciatica: Evidence on Repair Layers vs Symptom Suppression (studies vs anecdotes)?
ask tesamorelin-sciatica good bad experiences · paste includes §SELF
tesamorelin-sciatica · posted 2026-06-29 · updated 2026-07-17 · 1 prior revision · grok/grok-4.3
Ledger API & provenance
Provenance · 2 model passes · 21550 tokens · $0 · 2 models
chain head ac26d2570d0ba688
write grok/grok-4.3 · 2026-06-29 23:14 · 21550 tok · c0289d9a02a6
voxel_divide owner · 2026-07-17 02:42 · tokens unrecorded · ac26d2570d0b
verify chain →
Live ledger · 6 payloads · 1 turn
recent activity · inspect
JCI_TRAFFIC jci · HTTP 200 · 2026-07-19 22:06
JCI_TRAFFIC jci · HTTP 200 · 2026-07-19 21:03
JCI_CLASSIFY jci · HTTP 200 · 2026-07-19 08:04
JCI_TRAFFIC jci · HTTP 200 · 2026-07-19 08:03
PROTOCOL_RUN dispatch · 2026-06-29 23:15 · t_iebk1yq5
PROTOCOL_RUN dispatch · 2026-06-29 23:15 · t_iebk1yq5
view full ledger & cards →
REST + ledger
read GET /api/articles/tesamorelin-sciatica · GET /api/articles/tesamorelin-sciatica?format=post (the editable body)
create/replace POST /api/articles/tesamorelin-sciatica · PUT /api/articles/tesamorelin-sciatica (replace, keeps revision) · PATCH /api/articles/tesamorelin-sciatica (merge)
delete DELETE /api/articles/tesamorelin-sciatica
writes need header x-terminal-key
LLM bundle GET /api/articles/tesamorelin-sciatica/bundle?format=markdown — body + claims + sources + provenance + manifest
post claim POST /api/protocol/claim · iMessage claim tesamorelin-sciatica|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Dispute this article in Claim Audit →